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ABSTRACT 
OBJECTIVES: The objectives of this study were: (1) to determine prevalence of opioid 
analgesics prescribing for non-ED dental related visits in the Mississippi Medicaid population, 
(2) to assess predictors of receiving opioid analgesics following non-ED dental related events 
among Mississippi Medicaid beneficiaries, and (3) to determine prevalence of opioid analgesic 
prescribing for dental related emergency departments (ED) visits in the Mississippi Medicaid 
population. 
METHODS: A retrospective, cross-sectional, observational database analysis using Mississippi 
Medicaid administrative claims data from January 1, 2015 to December 31, 2016. Beneficiaries 
with dental related visits were included in this study. Descriptive statistics were utilized to assess 
the prevalence of opioid prescribing for ED and non-ED dental visit events in the study period. 
Logistic regression analyses were conducted to assess predictors of receiving an opioid 
prescription following a non-ED dental related visit. Adjusted odds ratios, 95% confidence 
intervals and p-values were calculated for the odds of receiving an opioid analgesic and the odds 
of receiving an opioid analgesic with a morphine equivalent daily dose (MEDD) greater than the 
median value of 25. 
RESULTS: A total of 16,409 dental visit events were identified and 27% of dental visit events 
were associated with an opioid prescription. Cleaning/preventive procedures had the lowest rate 
of opioid prescribing (16%) while tooth extraction procedures had the highest rate of opioid 
prescription (55%). Logistic regression showed that beneficiaries undergoing extraction 
procedures had six times higher odds to be prescribed an opioid than those undergoing 
cleaning/preventive procedures [OR=6.27, 95% CI: 4.64-8.46, P <0.0001]. Beneficiaries aged 18 
or younger were less likely to receive an opioid in comparison to beneficiaries ages 19 to 45 
years [OR=0.30, 95% CI: 0.27-0.33, P <0.0001]. Approximately 12% of opioid prescriptions for 
dental diseases had dosages of 50 morphine equivalents/day or higher; 53% of these 
prescriptions were written for more than a 3-day supply and 16% for more than a 7-day supply. 
Approximately 42% of dental related ED visits events were associated with an opioid 
prescription, and gum disease/periodontitis had the highest rate of opioid prescriptions for ED 
visits at 48%.  
 iii 
CONCLUSIONS: The findings of this study indicate that opioids are prescribed for many dental 
procedures. This study has a broader policy implication for the state of Mississippi regarding 
opioid abuse and misuse, drug utilization trend monitoring and curtailing opioid abuse by 
broadening the lens to the field of dentistry. 
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INTRODUCTION 
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Introduction 
Opioids are a class of drugs used to treat moderate to severe pain.  In the United States 
(U.S.), some opioids are available by prescription, while other opioids, such as heroin, are 
illegal to use. Some examples of prescription opioid analgesics include as oxycodone, 
hydrocodone, codeine, and morphine (Compton & Volkow, 2006).  Currently, there are 19 pure 
prescription opioids (not including combinations) that are approved by the Food and Drug 
Administration (FDA).  Many of the current opioids on the market are combination products 
containing one of the approved opioid medications. A list of all FDA approved opioid analgesic 
medications can be found in Appendix A (FDA Drug Safety Communication, 2016). 
The use of opioid medications for the treatment of various types of pain continues to 
increase (Birnbaum et al., 2011; U.S. Department of Health and Human Services, 2011). The 
hypnotic effect that opioids elicit have led to abuse and misuse when used for medical and non-
medical purposes. In 2010, it was estimated that 12.2 million people reported using pain 
relievers non-medically for the first time within the past year (Ashrafioun, Edwards, Bohnert, & 
Ilgen, 2014). With the increased use of opioids, there have also been increases in death due to 
opioid overdose. The Centers for Disease Control and Prevention (CDC) reported that the 
number of opioid-related poisoning deaths more than tripled from 1999 to 2003 (U.S. 
Department of Health and Human Services, 2011). Drug overdose is the leading cause of 
accidental death in the U.S with 47,055 lethal drug overdoses in 2014. Among these accidental 
deaths, 18,893 overdose deaths were related to prescription pain relievers  (Manchikanti, 2006). 
Additionally, data from the National Center for Health Statistics reported that opioid analgesic 
pain relievers were involved in more drug poisoning deaths than other specified drugs, 
including heroin and cocaine (Rice, Kelman, & Miller, 1991). In the U.S., abuse of prescription 
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pain medication continues to be a significant and growing problem and opioid use has taken a 
center stage in this epidemic. 
In addition to the mortality and addiction that occurs because of opioids, prescription 
opioid abuse has a substantial economic cost to society. The estimated societal cost of 
prescription opioid abuse in 2001 was $8.6 billion (Birnbaum et al., 2006).  A few years later, 
Birnbaum reassessed the societal cost of prescription opioid abuse in 2007 and estimated it to be 
$55.7 billion (Birnbaum et al., 2011). 
 
 Dental Prescribing of Opioid Analgesics  
Primary care providers account for approximately half of all prescribed opioid 
prescriptions that are dispensed (Daubresse et al., 2013).  Next to primary care physicians, 
dentists are the second leading prescribers of immediate-release opioids (Substance Abuse and 
Mental Health Services Administration, 2012), and have contributed significantly to the 
prescription opioid volume in the U.S. by prescribing 12% of all immediate release opioid drugs 
(Denisco et al., 2011). Opioid analgesics are generally used in dentistry for short-term pain 
management associated with dental surgical procedures, and they are among the most 
frequently prescribed drugs by dentists (Denisco et al., 2011; Moore & Hersh, 2013; Reece, 
2007). Therefore, dentists also potentially play a very important role in opioid abuse and misuse 
prevention (Moore, Nahouraii, Zovko, & Wisniewski, 2006b; Oakley, O’Donnell, Moore, & 
Martin, 2011). 
In recent times, physician and dental prescription practices have been under the public 
lens regarding opioid misuse, abuse, and diversion by patients in part due to their prescribing 
habits. Dental pain, like other forms of pain, is very subjective regarding severity measurement 
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and most pain scales are unreliable. Hence, in practice, dentists rely on patient complaint and 
symptoms experienced to determine the necessity to prescribe pain medications. Additionally, 
dentists are not aware of a patient’s history of substance abuse unless voluntarily reported by 
the patient (McCauley et al., 2016). 
Dentists are also usually limited in exposure to drug and opioid addiction training and 
reporting strategies, such as prescription drug monitoring programs (PDMPs) (Ashrafioun et al., 
2014; McCauley et al., 2016). Despite this, a limited number of studies regarding dental opioid 
prescribing practices and the frequency of multiple concurrent opioid prescriptions among 
dental patients have been conducted (Deyo et al., 2015; Hersh et al., 2011; Oakley et al., 2011). 
Similarly, very little is known about the extent to which dental patients report diverting 
prescription opioids intended for acute dental pain for purposes not intended by the dental 
prescriber (Ilgen et al., 2012). 
Dental clinics that provide affordable dental care, such as university dental training 
clinics, have been reported to commonly treat patients with alcohol-related problems and/or 
illicit drug use (Moore et al., 2006b). Another area of consideration when prescribing analgesics 
by dentists and physicians is determining the patients for whom opioid analgesics are necessary 
and appropriate, and if so, determining the dose and quantity that should be appropriately 
prescribed. This is partly due to the prevalence of substance and alcohol abuse that can be 
encountered within the dental patient population, and also because substance abusers frequently 
obtain prescription drugs from friends and family for non-medical purposes (Johnson, Hearn, & 
Barker, 2008).  
Regarding emergency department (ED) visits, the number of ED visits for dental pain in 
the U.S. increased from 1.1 million in 2000 to 2.1 million in 2010 (Wall et al., 2013).  Many 
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more patients with dental pain seek care at the ED and could be prescribed an opioid analgesic 
without an understanding of their substance abuse history which poses unique problems. 
(Mendonca et al., 2010; Reece, 2007). 
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Pain and Opioids  
Pain is one of the most common diagnoses in primary care facilities (Volkow & 
McLellan, 2011), and is presented as a complaint by nearly two-thirds of emergency department 
patients treated in the United States (U.S.) (Cordell et al., 2002). Opioid analgesics have 
become commonly used for the treatment for moderate to severe pain and have vastly improved 
the quality of life for many. Nonetheless, its addictive properties have also resulted in potential 
for abuse and misuse (Bhamb et al., 2006; Gudin, 2012; Victor, Alvarez, & Gould, 2009). Over 
time, the number of prescribed opioid analgesics, such as fentanyl, oxycodone, hydrocodone, 
and methadone, has increased. A report by Levy et al. (2015) on opioid prescription indicates 
that opioid prescription volume increased by 11.4% between 2007 and 2012 (Levy, Paulozzi, 
Mack, & Jones, 2015) and deaths due to the abuse and misuse of such analgesics has nearly 
doubled (Johnston, 2010).  
Opioid analgesics are typically prescribed for acute and chronic pain by primary care 
physicians, emergency room physicians, and dentists. In the U.S., the number of opioid 
prescriptions filled by pharmacies increased by 27% (from 174 million to 238 million) between 
2000 and 2011 (Manchikanti et al., 2012). As the use of opioids analgesics for pain 
management has increased, so has the incidence of opioid abuse and misuse (Manchikanti et al., 
2012). As a result of this increase, opioid analgesics have come under public scrutiny from 
policymakers, patient advocacy groups and clinicians (Okunseri, Okunseri, Xiang, Thorpe, & 
Szabo, 2014). 
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Opioid Abuse and Misuse 
Pain medications containing hydrocodone and oxycodone have been identified as the 
most common choice among prescription opioid abusers and misusers. A 2012 National Survey 
on Drug Use and Health (NSDUH) study estimated that approximately 4.5 million people, who 
12 years or older reported nonmedical use of pain relievers in the past month (Substance Abuse 
and Mental Health Services Administration, 2012).  
Opioid abuse and consequently overdose have been increasing steadily in the U.S. for 
over two decades. Accordingly, rates of prescription opioid poisoning and overdose have risen 
threefold between 1999 and 2008, and have outpaced popular illicit drugs, such as cocaine and 
heroin (Paulozzi, Jones, & Mack, 2011). Legitimate prescriptions, and the subsequent misuse 
(intentional and unintentional as well as diversions) of opioid prescriptions, constitute a major 
source of the current epidemic of opioid abuse (Inciardi et al., 2009; Shei et al., 2015; Voepel-
Lewis, Wagner, & Tait, 2015; Wisniewski, Purdy, & Blondell, 2008). Deaths as a result of 
opioid overdose have increased fourfold between 1990 and 2010, and it is estimated that about 
100 people die each day from an opioid related overdose (CDC, 2013; Coben et al., 2010).  
Katz et al. (2007) defines drug misuse as the “use of a medication other than as directed 
or as indicated, whether willful or unintentional, and whether harm results or not”, and drug 
abuse as “any use of an illegal drug or the intentional self-administration of a medication for a 
non-medical purpose”. Consequences of opioid misuse include opioids poisoning and overdose, 
and this can occur among individuals who misuse a duly prescribed opioid by taking the 
medication differently from how it was prescribed. It is important to note that there are other 
ways in which patients abuse and misuse medications. For example, “doctor shopping” is a 
phenomenon in which patients visit multiple physicians to obtain opioids in amounts that are 
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not intended for medical purposes (Cepeda, Fife, Chow, Mastrogiovanni, & Henderson, 2013). 
Doctor shopping also poses other problems because of the potential for illegitimate drug misuse 
and possible distribution to others without a prescription (Rigg, Kurtz, & Surratt, 2012). A prior 
study showed that about 5 to 23% of all prescription opioids dispensed were used for non-
medical purposes (Savage, Covington, Gilson, Gourlay, Heit, & Hunt, 2004) with immediate-
release (IR) opioids such as hydrocodone and oxycodone being the most commonly abused 
(Substance Abuse and Mental Health Services Administration, 2012). 
The major sources of obtaining prescription drugs that are used for non-medical 
purposes are family members, friends and in some cases through prescriptions (Substance 
Abuse and Mental Health Services Administration, 2012).  Research by the National Survey on 
Drug Use and Health (NSDUH ) survey reported that in 2008/2009, among people over 12 
years of age who had used pain relievers non-medically in the prior year, 70% obtained these 
drugs from friends or family while 4.8% obtained their pain relievers from drug dealers 
(Substance Abuse and Mental Health Services Administration, 2012). A 2008 study in the state 
of Utah reported that 72% of respondents who were prescribed an opioid pain medication had 
some left over, and 71% of those with leftover medication kept it for future use (CDC, 2010). 
Additionally, unintentional diversion, in which medication is obtained from family and/or 
friends, also has been consistently reported as a major source of opioids among adolescent 
abusers (McCabe, West, & Boyd, 2013a). 
Adolescents, particularly, are at risk for opioid overdose. In 2009, the National Institutes 
of Health’s National Institute on Drug Abuse convened, in Rockville, MD, to examine how 
opioid prescribing pattern in dental settings might contribute to opioid abuse among adolescent 
patients. This meeting indicated the need for a greater understanding of opioid prescribing 
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practices in dental offices, including the quantity typically prescribed by dentists as well as the 
quantity that is needed for adequate post procedural pain management in order to prevent 
addiction, misuse and abuse (Denisco et al., 2011). To highlight the concern regarding the 
proliferation of hydrocodone and oxycodone products, the Drug Enforcement Agency (DEA) 
recently rescheduled hydrocodone products as Schedule II controlled substances (Drug 
Enforcement Administration, 2014). 
 
Cost Associated with Opioid Abuse and Misuse 
Hansen et al. (2011) estimated total costs to be $53.4 billion (2006) for nonmedical use 
of prescription opioids, of which $42 billion (79%) was attributable to lost productivity, $8.2 
billion (15%) to criminal justice costs, $2.2 billion (4%) to drug abuse treatment, and $944 
million (2%) to medical complications. Workplace costs related to absenteeism, lost wages and 
disability accounted for $25.6 billion (46%), health care costs accounted for $25.0 billion 
(45%), and criminal justice costs accounted for $5.1 billion (9%) (Birnbaum et al., 2011). 
McAdam-Marx et al. (2010) evaluated the average yearly cost after an index opioid 
abuse diagnosis among Medicaid beneficiaries and reported that total costs were significantly 
higher for the abuse/dependence patients ($14,537) than for patients who were not taking 
opioids ($8,663) (P < .001). When controlling for baseline characteristics, adjusted costs 
continued to be higher for abuse/dependence patients ($23,556 versus $8,436; P < .001) 
(McAdam-Marx et al., 2010).  
Inocencio et al. (2013) reported the average direct cost per poisoning or overdose event 
was estimated to be $4,006. However, the average direct costs per poisoning were lower for 
heroin when compared to opioids ($3,198 vs. $4,255). The mean ED treatment cost for all 
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opioids was estimated to be $1,832. Total estimated direct annual costs to the U.S. were 
estimated to be $2.2 billion.  Prescription opioid poisoning accounted for 80% of all direct 
medical costs. Specifically, total direct costs were highest for oxycodone ($616 million), 
hydrocodone ($428 million), methadone ($289 million) and unspecified opioids ($350 million) 
(Inocencio et al., 2013). 
 
Opioid Overdose Deaths 
The United States is currently going through an epidemic due to drug overdose deaths. 
Since 2000, there has been a 137% increase in the number of deaths from drug overdoses, 
including a 200% increase in the rate of overdose deaths involving opioids (i.e. opioid pain 
relievers and heroin) (Rudd et al., 2016). Unintentional poisoning in general currently 
represents the leading cause of injury related death in the U.S. for adults ages 25–64 years 
(Murphy et al., 2013; U.S. Department of Health and Human Services, 2011). 
The CDC analyzed mortality data to investigate trends of drug overdose deaths, and the 
types of opioids associated with overdose deaths. In 2014, a total of 47,055 drug overdose 
deaths occurred in the U.S., representing an increase of 6.5% in one year, from 13.8 per 100,000 
persons in 2013 to 14.7 per 100,000 persons in 2014 and increased to 16.3 per 100,000 persons 
in 2015 (Rudd et al., 2016). 
Miller et al. (2015) reported a correlation between the type of opioid and potential for 
overdose. After adjustment for age, sex, and opioid dose, patients who received long-acting 
opioids were two times more likely to overdose as compared to patients who received short-
acting opioids. (Hazard Ratio, 2.33; 95% CI: 1.26-4.32). The risk of overdose associated with 
long-acting opioids was particularly significant during the first two weeks after commencement 
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of treatment (Hazard Ratio, 5.25; 95% CI: 1.88-14.72) (Miller et al., 2015).  Additionally, the 
rate of drug overdose deaths increased significantly for males and females, in people aged 25–
44 years and ≥55 years, in non-Hispanic whites and non-Hispanic blacks. Geographically, in the 
South, Northeast and Midwestern regions of the US, rates of overdose deaths caused by opioids 
also increased significantly, from 7.9 per 100,000 in 2013 to 9.0 per 100,000 in 2014, a 14% 
increase in one year (Rudd et al., 2016). 
 
Prevalence of Opioid Prescribing Among Dentists 
Data from IMS Health also shows that dentists prescribe about 6.4% of all opioids 
dispensed in the US; which is equivalent to 18.5 million opioid prescriptions in 2012 (Levy et 
al., 2015). Denisco et al. (2011) surveyed oral and maxillofacial surgeons and reported that they 
performed an average of 53 (range 45 to 69) third-molar extractions per month. Extrapolating 
this information to all 5,542 practicing oral and maxillofacial surgeons in the U.S. at the time, 
an estimate of 3.5 million third-molar extractions were conducted annually among oral and 
maxillofacial surgeons, excluding general dentists (Moore, Nahouraii, Zovko, & Wisniewski, 
2006a). Hence, up to 3.5 million people may be exposed to the possibility of obtaining opioid 
analgesics through dental procedures (Denisco et al., 2011). 
In a statewide survey conducted in West Virginia in 2010, practicing dentists in the state 
were asked about their prescribing patterns and experience with drug and substance abuse, 
misuse and diversion. Among the dentists who did not prescribe opioids, the most commonly 
prescribed pain relievers were non-steroidal anti-inflammatory drugs (NSAIDs) (64%), 
followed by acetaminophen (28%). Among those who prescribed opioids, the most commonly 
prescribed opioid was hydrocodone combined with acetaminophen (73%) (Denisco et al., 
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2011). There was considerable variation regarding the amount of opioids prescribed following a 
third molar extraction procedure. However, the duration of use was typically between two to 
five days in about 86% of the cases. More importantly in the fight against drug diversion, about 
41% of dentists who prescribed an opioid expected patients to have some medication leftover 
(Denisco et al., 2011).    
Prior research has focused on opioid prescribing by dentists after molar extractions, 
reporting that most (85.0%) dentists prescribed an opioid, most often hydrocodone with 
acetaminophen, with instructions to take for pain as needed (Haegerich, Paulozzi, Manns, & 
Jones, 2014).  A pilot study by Ilgen, Edwards and Kleinberg (2012) on opioid prescriptions by 
dentists provided an estimate of the prevalence of nonmedical use of opioids and diversion 
among dental patients receiving care at an outpatient dental clinic. The study reported that 
37.9% of dental patients reported some form of nonmedical use of prescription opioids and 
6.5% reported diverting their initial dental medication; which indicates that dental patients may 
be at a risk of opioid medication abuse and misuse (Ilgen et al., 2012).  
Various government public health agencies such as the Office of National Drug Control 
Policy, the Department of Health and Human Services, and the National Institute on Drug 
Abuse have identified prescribers as critical intervention points in the fight against the 
prescription drug abuse epidemic (U.S. Department of Health and Human Services, 2015; 
Volkow, 2014). A study in a national health care plan with about 2 million beneficiaries 
reported that providers who were specialists were more likely to prescribe extended release 
opioids for pain that lasted at least 60 days (Victor et al., 2009). In a large national sample with 
121 million patients including prescription data from more than half of the retail pharmacies in 
the U.S, it was reported that primary care physicians (i.e., general practitioners, family medicine 
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practitioners and internists) prescribed more opioids (28.8%) to prescribe opioids, compared to 
dentists (8.0%) and orthopedic surgeons (7.7%) (Volkow, McLellan, Cotto, Karithanom, & 
Weiss, 2011). 
Rigoni reported, in 2003, that dentists prescribe 12% of immediate-release opioids in the 
U.S, preceded only by family physicians, who prescribe 15% of immediate-release opioids 
(Rigoni, 2003). Due to information showing that immediate-release opioids constitute the 
majority of nonmedical use of opioids, dentists have some contribution to this phenomenon 
(Denisco et al., 2011). 
Dentists have reported prescribing opioid medication for the management of pain for 
procedures such as root canal, implants and tooth extraction. Prior research also consistently 
shows that most opioid prescriptions prescribed by dentists were for immediate-release 
formulations, specifically various hydrocodone combinations (Weiland et al., 2015).  
A pilot study by Ilgen et al. (2012) on opioid prescriptions by dentists provided an initial 
estimate of the prevalence of nonmedical use of opioids and diversion among dental patients 
receiving care at an outpatient dental clinic. The study showed that 37.9% reported some form 
of nonmedical use of prescription opioids and 6.5% of respondents reported diverting their 
initial dental medication; which indicates that dental patients may be at an increased risk of 
opioid medication abuse and misuse (Ilgen et al., 2012). 
Dentists prescribe about 1 of every 10 immediate-release opioids dispensed, and opioid 
prescriptions account for a high proportion of all dental prescriptions (Denisco et al., 2011; 
Ringwalt et al., 2014). Prior literature suggests that (a) dental patients are potentially vulnerable 
to personal abuse and misuse of opioid medication (Ashrafioun et al., 2014 ), (b) dental patients 
regularly have unused leftover opioid medication that constitutes a significant proportion of 
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nonmedical use (McCabe, West, & Boyd, 2013b), and (c) access to dental care at a community 
level is associated with higher rates of opioid abuse because there is an increased availability of 
prescription opioids (Wright et al., 2014). However, dentists’ prescribing patterns may be 
impacted by increased regulation and prescribing requirements associated with the DEA’s 
decision to reschedule hydrocodone, which could potentially lead to consideration of 
alternatives for the management of post-procedural pain (Golembiewski, 2015; Curro, 2013) 
Dentists regularly encounter patients with addiction which is not just limited to opioid 
addiction, nevertheless many dentists say they have limited exposure to information regarding 
addiction treatment which includes but not limited to screening, interventional and referral 
programs to assist addicts (Ilgen et al., 2012; McNeely et al., 2013). Prescription opioid 
medications can constitute a risk to those affected by opioid dependency because these 
prescription while written legitimately for pain control, can be sold on the street, stolen by 
family members or taken in excess quantities not recommended by the prescriber (CDC, 2013). 
Adverse effects of opioid misuse can include the development of more chronic and 
severe substance use, overdose deaths and other unintentional fatalities (Bohnert et al., 2011; 
Meyer, Patel, Rattana, Quock, & Mody, 2014; Yokell et al., 2014). Hasegawa et al. (2014) 
reported that ED visits related to opioid overdose have quadrupled between 1993 to 2010 
increasing from 19 to 63 per 100,000 ED visits (+235%; Ptrend < 0.001).  Imtiaz et al., (2014) 
demonstrated that there have been corresponding increases in admission rates, morbidity, and 
mortality related to opioid use by showing that consumption levels of prescription opioids were 
very strongly correlated with morbidity and mortality measures per 10,000 people (r =0.95) and 
opioid overdose deaths per 100,000 people (r =0.99) (Imtiaz, Shield, Fischer, & Rehm, 2014). 
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Despite increased attention to physician prescribing practices, as well as the role of the 
dental prescriber in promoting and preventing opioid misuse, abuse, and diversion, limited 
representative data exists regarding dental opioid prescribing practices and the frequency of 
multiple concurrent opioid prescriptions among dental patients (Denisco et al., 2011; Haegerich 
et al., 2014; Nuckols et al., 2014). 
Prescription opioid misuse and abuse has increased over the past decade and can been 
attributed in large part to higher rates of opioid prescribing. Various initiatives across the nation 
such as prescription drug monitoring programs PDMPs have sought to prevent and reverse 
opioid abuse and consequently overdose death through education and increasing access to 
naloxone (Wheeler, Davidson, Jones, & Irwin, 2012). Despite the concern regarding the misuse 
and abuse of prescription opioids, physicians continue to be able to prescribe them with a 
balance to the risk and also ensuring that the patients receive the best possible care for their pain 
(Inocencio et al., 2013). 
Also, literature suggests that dentists do not routinely use prescription drug monitoring 
programs (PDMP) when they prescribe opioid medications (Herman, 2011). PDMPs are 
databases collected from pharmacies on dispensed controlled substances such as opioids and in 
some cases benzodiazepines and makes them available to physicians, dentists and pharmacists 
with the aim of identifying patients who are at risk for, abuse or misuse (Hansen, 2015; Jena, 
Goldman, Weaver, & Karaca-Mandic, 2014; Paulozzi, 2012). 
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Prescription Drug Monitoring Programs 
Prescription Drug Monitoring Programs (PDMPs) are state run electronic databases that 
collect data from pharmacies on dispensed controlled substances and make it available to 
authorized prescribers and pharmacists in order to monitor and identify patients that are at a 
high risk of opioid abuse (Hansen, 2015). Information from PDMPs are valuable in the 
identification of patients with concurrent opioid medications which is an indicator of risk for 
opioid abuse, misuse and overdose (Green et al., 2013; Jena et al., 2014; Paulozzi, 2012).  
By October 2012, all 50 states in the U.S. had enacted laws establishing a prescription 
drug monitoring program, with 42 states having operational programs for monitoring in place   
(Alliance of States with Prescription Monitoring Programs, 2012). PDMPs allow for active 
monitoring of prescribing and dispensing records for selected drugs of abuse and are intended to 
aid providers, including dentists, as well as law enforcement to control prescription drug abuse, 
misuse and controlled substance use history. PDMP data is used differently depending on the 
state, nonetheless in most states, information is provided to pharmacy and other health care 
professionals and, in some cases can be provided to law enforcement (Inocencio et al., 2013). 
Some states have enacted legislation that mandates the use of PDMPs prior to prescribing 
opioid substances (Rasubala, Pernapati, Velasquez, Burk, & Ren, 2015). Dentists also reported 
never using the PDMP because they were not aware it existed or did not know how to access it 
(Ilgen et al., 2012, McNeely et al., 2013). However, dentists reporting PDMP use found it at 
least somewhat helpful and PDMP use contributed to prescribing fewer opioid doses 
(McCauley, Leite, Melvin, Fillingim, & Brady, 2016). 
Evidence from research suggests that prescribers may have incorrect perceptions of their 
patients’ risk for drug abuse or misuse (Bartley et al., 2015). Hence, regular use of PDMP data 
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to inform and improve prescription decisions is highly recommended (Brady et al., 2014; 
Haegerich et al., 2014; Haffajee, Jena, & Weiner, 2015; Rasubala et al., 2015). Training 
prescribers like dentists on PDMP use, patient education regarding addiction, is a key national 
strategy to prevent opioid abuse, misuse and diversion (US Department of Health and Human 
Services, 2015). Proper training in identification of drug misuse was one major reason why 
dentists’ choose to use PDMP’s prior to prescribing, and an overwhelming majority of dentists 
have an interest in continuing education regarding opioid abuse and misuse as most current 
dentists have no training in strategies to identify and prevent opioid misuse in their practice 
(McCauley et al., 2016).Various reasons have been identified as possible barriers to the 
adoption of PDMPs and these include a general lack of awareness, barriers to accessibility, 
quality and interpretability of data, uncertainty regarding how to respond in instances of 
suspected misuse or abuse, litigation fears and privacy concerns (Deyo et al., 2015; Griggs, 
Weiner, & Feldman, 2015; Islam & McRae, 2014; Rutkow, Turner, Lucas, Hwang, & 
Alexander, 2015). 
Research on potential factors associated with physician opioid prescribing practices has 
been limited and inconclusive. While some investigations have linked such prescriptions to pain 
scores (Fanciullo, Hanscom, Seville, Ball, & Rose, 2001), some others have not (Breckenridge 
& Clark, 2003; Turk & Okifuji, 1997). Some clinicians suggest instead that patients’ pain-
related behaviors, particularly their distress and disability levels, might be more associated with 
the prescribing practices of providers than pain scores. The role of practitioner specialty as a 
factor in the prescribing of opioid medication remains conflicting due to the complex nature of 
drug abuse (Heins et al., 2006; Heins, Homel, Safdar, & Todd, 2010). The lack of substantiated 
evidence regarding providers and prescription of opioids this has led researchers to conclude 
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that opioid prescribing habits are largely idiosyncratic and based largely on providers’ beliefs 
regarding their appropriateness (Tamayo-Sarver, Dawson, Cydulka, Wigton, & Baker, 2004). 
This necessitates further research into the role of practitioners as a factor in the debate on opioid 
abuse. 
 
Emergency Department Use for Dental Problems 
Emergency departments (EDs) are a very crucial point of entry into the health care 
system, particularly for people who have difficulty accessing routine preventive health care 
services. This problem is more pronounced for dental related problems because an estimated 
44% of Americans lack dental insurance. Due to this, many experience difficulties in access to 
dental services (CDC, 1997). 
According to the National Hospital Ambulatory Medical Care Survey (NHAMCS), the 
number of dental ED visits in the U.S. increased from 1.1 million in 2000 to 2.1 million in 2010, 
representing an increase in the rate and signifies an increasing reliance on emergency services for 
dental related procedures (Wall et al., 2013). In 2006, there were 120,033,750 hospital-based 
emergency department visits across the United States and among these, a total of 330,757 visits 
to hospital ED visits were primarily attributed to dental caries alone. Children accounted for 
24,982 visits, whereas adults accounted for 305,775 visits. Fifty-two percent of all visits 
occurred among females (Nalliah et al, 2010).  
According to Okunseri et al. (2015), 50.3% of patients with a non-traumatic dental 
related visit to the emergency department received an opioid, and the rates for each specific 
prescribed opioid examined (hydrocodone, oxycodone, and codeine) were 31.6%, 12.3%, 4.1%, 
respectively (Okunseri et al., 2015). The proportion of Medicaid enrollees with non-traumatic 
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dental conditions was 29.8% and represented the highest rate compared to other forms of 
insurance (Okunseri et al., 2015).  
Income plays a huge role in predicting ED visits with close to 38% of all visits by both 
children and adults occurring among individuals residing in lower income areas. This highlights 
income based disparities in dental healthcare access and emergency room utilization in the 
United States (Nalliah et al., 2010). A dental ED visit study showed that uninsured individuals 
account for about approximately 45% of all emergency room dental related visits and close to 
20% of all visits by children occurred among children who were uninsured. Medicaid was also 
the most common payer for all visits by children, accounting as the payer for nearly 53% of all 
visits (Nalliah et al., 2010).  
A dental health study in New York found that 67% of oral health related visits to 
emergency departments by children who were younger than 6 years of age were attributable to 
dental caries (Wadhawan et al., 2003). Wilson et al. (1997) reported that 73% of children 
presenting for dental emergencies in an ED had a primary diagnosis of dental caries. 
Additionally, Graham et al. (1999) examined the incidence of pediatric emergency room visits 
for non-traumatic, preventable dental disease, and reported that 48% of cases had a primary 
diagnosis of caries. Evidently, dental caries is an important personal and public health issue 
among children. In general, patients who present at an ED with a dental condition would be 
better served in a dental office setting due to the availability of definitive care and the likelihood 
of continuity of care as well as the ability to have a one on one encounter with the dental 
provider (Okunseri et al., 2014). 
Emergency departments are an important point of care for dental-related problems, 
particularly for people who are uninsured. Emergency departments and their providers should be 
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prepared and equipped to diagnose, provide basic treatment, and, if possible, ensure that follow-
up care for dental problems within dental offices should be carried out (Lewis, Lynch, Johnston, 
2003). Emergency departments may even face greater numbers of patients with dental 
complaints if the uninsured population increases and if the current barriers (such as income and 
insurance coverage) to accessing dental care are not addressed. There is a need for dental training 
for emergency care providers, as well as for improving dental care during and after ED visits, 
should be assessed (Lewis, Lynch, Johnston, 2003).  
 
Study Significance 
This study examined the patient demographic characteristics as well as disease factors 
that potentially influence dental patients receiving opioid prescriptions from dentists. Patient 
level information gives policy makers an understanding of the patient population exposed to 
opioids through the dentist. Additionally, examining emergency department visits with dental 
diagnoses can help improve understanding of the burden of emergency department visits for 
dental purposes, which can inform policy and policy regarding the potential for opioid abuse 
through opioids administered through the emergency department in the Mississippi Medicaid 
population.  
There is limited literature on the prescribing patterns of dental providers and even less so 
on predictors of dental opioid prescribing. This study attempts to assess dental opioid 
prescriptions by understanding the dentist who prescribes and the patient who obtains these 
prescriptions. Prior research has examined the prevalence of emergency department visits due to 
dental caries in children. However, this study presents a view of emergency department visits for 
dental problems and opioid prescriptions associated with them.   
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METHODOLOGY 
Study Objectives 
The objectives of this study were: 
1) To determine prevalence of opioid analgesics prescribing for non-ED dental related 
visits in the Mississippi Medicaid population. 
2) To assess predictors of receiving opioid analgesics following non-ED dental related 
events among Mississippi Medicaid beneficiaries. 
3) To determine prevalence of opioid analgesic prescribing for dental related emergency 
departments (ED) visits in the Mississippi Medicaid population. 
Data Source 
 The Mississippi Division of Medicaid is a state branch of the United States program that 
was designed to provide health coverage for indigent families and individuals. Medicaid is a 
means tested program which is jointly funded by the Federal government and state government, 
but it is administered by the individual states. 
Mississippi Division of Medicaid administrative claims data files were used for this 
study. The data files include information about enrollment and eligibility; inpatient, outpatient 
and emergency department services; prescription drug claims; costs; dates of service; and 
demographics for each beneficiary.  
Mississippi Medicaid Administrative Claims Database 
The Medicaid administrative claims make up the database.  To protect patient privacy, 
all the beneficiary files were de-identified.  These files include: enrollment, inpatient, 
outpatient, medical, pharmacy, provider information.  
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The Medicaid beneficiary master file contains enrollment information for all Medicaid 
beneficiaries. This file contains patient data such as date of birth, gender, race, basis of 
eligibility, dual eligibility status, insurance type, monthly enrollment status, and county of 
residence. 
The inpatient claims file is a claim level file that contains information of complete 
hospital stay records for beneficiaries who used inpatient services including diagnoses (e.g., 
ICD-CM), Current Procedural Terminology (CPT) codes, ED visits, discharge status, length of 
stay, and payment amount. 
The medical claims files are claim level files that contain information related to office-
based visits, diagnosis (e.g., ICD-CM), procedure codes (e.g., CPT) date of service, provider 
type, and amount paid. Claims in medical file are generated from physician’s private practice. 
The National Provider Identifier (NPI) is a unique 10-digit identification number for 
health care providers, including both organizations and individuals. This file contains provider 
information including provider type, description, state of practice, county of practice. 
The outpatient claims file is also claim level file that provides information regarding 
hospital-outpatient visits, diagnosis codes (e.g., ICD-CM), procedure code (e.g., CPT), date of 
service, and billing information. Claims in the outpatient file are generated in hospital settings.  
The prescription claims file is a claim level file that contains information related to filled 
prescriptions. These claims include: the drug name of the filled medication, dispense date, 
quantity supplied, number of refills, number of days supplied, amount paid, and National Drug 
Code (NDC).  
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Ethical Considerations  
Application for human subjects research was submitted and approved by the 
Institutional Review Board at The University of Mississippi, University, MS.  
 
Study Design 
This study is a retrospective, cross-sectional, observational database analysis using 
Mississippi Medicaid administrative claims data. This study period was from January 1, 2015 to 
December 31, 2016. The Mississippi Medicaid administrative database contains a beneficiary 
master file, inpatient claims file, outpatient claims file, medical claims file, and prescription 
claims file. Each of these files were used for this study. 
 
Study Sample 
Inclusion Criteria 
Objective 1 and 2:  
• Patients with at least one medical claim for a non-ED dental event. 
• Patients with a claim for an opioid analgesic prescription medication within 3 days of a 
dental event were included in the opioid use group. 
Objective 3:  
• Patients with a claim for ED visit with dental disease diagnoses.  
• Patients with a claim for an opioid analgesic prescription medication within 24 hours of 
the ED visit were included in the opioid use group.  
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Exclusion Criteria 
Patients that were dual eligible (patients with both Medicare and Medicaid coverage), in hospice 
care or long-term care facilities were excluded from the analysis. 
 
Study Measures and Operationalization 
Demographic/ Patient variables 
Patient demographic information was obtained from the Medicaid beneficiary Masterfile. The 
demographic variables included in the study were:  
i. Age: 0-18 years, 19-44 years, 45-59 years, and 60+ years  
ii. Gender: Male or Female 
iii. Race: White/Caucasian, Black/African American, Hispanic, Native American, Other 
Opioid Medication/Drug Variables 
i. Identification of opioid analgesic variables 
To identify opioid prescriptions, national drug codes (NDC) for opioid medications were 
identified in the Medicaid data using the NDC Masterfile utilizing therapeutic categories 
that contains all prescription opioids, strength, dosage, form, and formulation for each 
drug prescribed. The quantity, number of days supplied, and the date the 
prescription was written and dispensed, were included for each prescription.  
ii. Morphine equivalent dose 
Morphine Equivalent Daily Dose (MEDD) was used to report the relative daily 
strength of the opioid analgesics prescribed for dental events. MEDD is calculated by 
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multiplying the quantity of the prescription for each day of supply by its strength (in 
milligram equivalents) and a conversion factor, specific to the drug prescribed (Braden et 
al., 2009). The CDC has a cautionary warning on the prescription of opioids with 
morphine equivalents greater than 50 MEDD/day (Dowell, D., Haegerich, T. M., & 
Chou, R., 2016). In this study, we subdivided MEDD into 4 categories: Less than 50 
MEDD, 50 to 89 MEDD, 90 to 119 MEDD, and greater than or equal to 120 MEDD.  
iii. Number of days supplied 
Number of days supplied signifies the number of days the opioid medication was 
intended for use. Due to the acute nature of dental pain, this variable was measured from 
the pharmacy claims and categorized into 0-3 days, 4-7 days, 8-15 days, 16-30 days and 
greater than 30 days. 
iv. Emergency department visits 
Emergency department(ED) visits were identified using the procedural codes 99281-
99285. This represents the visit code by severity of the situation and extensiveness of 
care evaluation. 
v. Provider categories: 
General Practice Dentists 
Pediatric Dentists 
Orthodontists, Oral and Maxillofacial surgeons 
MD-Other: Student trainee/Internists, Physicians/Dentists without a specific self-reported 
identifier  
 
Dental Event Variables  
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Ten dental visit events were identified using ICD-9-CM and ICD-10-CM codes. The list 
of ICD-9 and ICD-10 codes for the dental procedures of interest used in this study can be found 
in Appendix B.  
International Classification of Diseases (ICD) codes are a set of codes developed by the 
National Center for Health Statistics (NCHS). ICD codes serve as a useful tool in the 
classification of morbidity data for health records, medical care review, and ambulatory and 
other health care programs, as well as for basic health statistics. ICD codes are used to classify 
diseases and a wide variety of signs, symptoms, abnormal findings, complaints, social 
circumstances and external causes of injury or disease. Nearly every health condition can be 
assigned to a unique category and given a code, up to six characters long.  
The United States Department of Health & Human Services and the Centers for 
Medicare and Medicaid Services (CMS) created ICD-9-CM as an extension of the Ninth 
Revision, International Classification of Diseases (ICD-9), which the World Health 
Organization (WHO) established to track mortality statistics across the world. ICD-10-CM is 
the US clinical modification of the World Health Organization’s ICD-10. ICD-9 codes will also 
be used because ICD-10 codes were not implemented until October 2015. Both ICD-9 and ICD-
10 codes were used to identify the various dental diagnosis made by the dental providers. A list 
of the ICD-9 and ICD-10 codes for dental procedures were developed using the Vermont 
Medicaid Portal dental ICD code database and ICD-10 Code Search (Vermont Medicaid, 2015; 
ICD-10 Code Search, 2017).   
 
Statistical Analysis 
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All data were analyzed using the Statistical Analysis System (SAS®) version 9.5 (SAS 
Institute Inc., Cary, NC).  An a priori alpha level of 0.05 was used to evaluate significance for 
all analyses.  
Objective 1: Prevalence of opioid analgesics prescribing for dental related visits in the 
Mississippi Medicaid population 
Descriptive statistics 
i. Demographic/Patient level information: Frequencies and percentages were 
calculated for all variables (age, gender, race/ethnicity), mean and standard deviation 
was also computed for age (continuous variable).  
ii. Dental event information: For each dental event category, the total number and 
percentage of events in each category, opioid analgesic prescription rate per event 
category, morphine equivalent daily dose (MEDD) categorized into (less than 50, 50 
to 89, 90 to 119, greater than 120) in each category, mean and standard deviation of 
opioid medication days’ supply per category were provided.  
iii. Medication level information: Frequency and percentages of days supply of 
medication and type of opioid medication prescribed per dental visit event category. 
PROC FREQ, PROC MEANS and PROC TABULATE procedures in SAS® was used to 
develop frequency tabulations.  
 
 
 
 
 30 
 
 
Objective 2: Predictors of receiving opioid analgesics following a dental related event 
among Mississippi Medicaid beneficiaries 
A logistic regression model was developed to assess the relationship between predictors 
(patient/sociodemographic variables) and dental events.  
In the first logistic regression model, the predictors were age, race, gender, dental visit 
event category and prescribing dentist specialty. The dependent variable was the odds of 
receiving an opioid following a dental related visit.  
Another logistic regression model was conducted with the dependent variable being 
receiving an opioid with a Morphine Equivalent Daily Dose (MEDD) greater than 25 (median 
value), following a dental visit event. The predictors were age, race, gender, dental visit event 
category and prescribing dental specialty. 
The PROC LOGISTIC procedure in SAS® was used to logistic regression model. Odds 
ratios, 95% confidence intervals and p-values were obtained for the logistic regression models.  
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Objective 3: Prevalence of opioid analgesic prescription for dental related emergency 
department (ED) visits 
i. Demographic/Patient level information: Frequencies and percentages were 
calculated for all variables (age, gender, race/ethnicity), mean and standard deviation 
was also computed for the continuous variable (age).  
ii. Dental event level information: For each dental event category, the total number and 
percentage of events in each category, opioid analgesic prescription rate per disease 
category, morphine equivalent daily dose (MEDD) categorized into (less than 50, 
50-89, 90-119, greater than 120) in each event category, mean and standard 
deviation of opioid medication days’ supply per category was provided.  
iii. Medication level information: Frequency and percentages of days supply of 
medication and type of opioid medication prescribed per dental visit event category 
were calculated. 
PROC FREQ, PROC MEANS and PROC TABULATE procedures in SAS® was used to 
develop frequency tabulations.  
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RESULTS 
Study Sample 
During the period of January 1, 2015 to December 31, 2016 in the Mississippi Medicaid 
data, a total of 12,388 beneficiaries had at least one dental event during the study period, and 
2,673 beneficiaries had a claim for an opioid within 3 days of a dental visit. Figure 1 shows the 
sample selection chart for patient level information. 
    
  
 
 
 
  
 
 
 
 
 
 
             
                                                
 
 
 
                                    
 
      Figure 1: Sample selection chart (Patient level information) 
  
 
OBJECTIVE 1 
Prevalence of opioid analgesics prescribing for non-ED dental related visits in the Mississippi 
Medicaid population. 
i. Patient level information 
Beneficiaries 
identified with at least 
one dental event in the 
study period 
 
12,388 
 
 
 
12,388 
 
 
Beneficiaries 
with a claim for 
an opioid 
analgesic 
medication 
within 3 days   
 
2,673 
 
 
 
12,388 
 
 
Beneficiaries 
without a claim 
for an opioid 
analgesic 
medication 
within 3 days   
 
9,715 
 
 
 
12,388 
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African Americans accounted for 58.98% of the population, while Caucasians made up 
34.40% of the population. The majority of the sample was female (58.04%) and 67.63% of the 
sample population was below the age of 18, while 27.66% of the population was between the 
ages of 19 to 44 years. Table 1 provides frequency tabulations for the sample population 
demographic characteristics.  
 
Table 1: Sample population demographic characteristics 
Demographic Characteristics 
N=12,388 
 
                                    n                                   % 
Age (Mean= 16.37, SD=15.27)   
  0-18 years 8,378  67.63 
19-44 years 3,426  27.66 
45-59 years 495  4.00 
60+ years 89  0.72 
Race/Ethnicity   
Caucasian 4,261 34.40 
African American 7,307 58.98 
Hispanic 233 1.88 
American Indian 86 0.69 
Other 501 4.04 
Gender   
Female  7,190  58.04 
Male 5,198 41.96 
 
Overall, 21.58% of the beneficiaries who had at least one dental event received an opioid 
analgesic prescription. Among adults aged between 19 years to 44 years, 45.83% of patients who 
had at least one dental event received an opioid medication within 3 days. Among adults aged 
between 45 years to 59 years, 38.79% received an opioid medication within 3 days while only 
26.97% adults aged above 60 years received an opioid within 3 days following a dental visit. 
Children below the age of 18 received the lowest proportion of opioids, among children below 
18 years, only 10.59% received an opioid medication within 3 days. Table 2 provides the 
proportion of patients receiving an opioid within 3 days following a dental visit. 
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Table 2: Proportion of patients receiving opioid medication within 3 days following a dental 
visit 
Demographic Characteristics 
 
         Total population                Proportion receiving an opioid     
                           n                                n                                % 
All                     12,388                          2,673                         21.58 
Age (Mean= 16.37, SD=15.27)    
0-18 years     8,378  887 10.59 
19-44 years 3,426  1,570 45.83 
45-59 years 495  192 38.79 
60+ years 89  24 26.97 
Race/Ethnicity    
Caucasian 4,261 920 21.59 
African American 7,307 1602 21.92 
Hispanic 233 44 18.88 
American Indian 86 5 5.81 
Other 501 102 20.36 
Gender                                       
Female  7,190  1,875 26.08 
Male 5,198 798 15.35 
 
ii. Dental event level information 
Of the 12,388 beneficiaries who met the inclusion criteria, a total of 16,409 dental events 
were identified. Dental events were categorized into ten distinct categories. Overall, 26.70% of 
the dental events had an associated opioid analgesic prescription within 3 days. Extraction/loss of 
tooth events accounted for the highest rate of opioid prescriptions (54.71%), while 42.37% of 
root canal and endodontic treatment procedures were associated with the prescription for an 
opioid medication. 
Cleaning, preventive and cleaning procedures category had the highest opioid average 
days’ supply with a mean of 15.78 days. Dental caries category had an average days supply of 
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5.61 days while root canal procedures had an opioid average days supply of 10.68 days. Overall, 
across all dental conditions, the average days’ supply of opioid medication was 5.5 days. 
Dental caries was the most common dental disease category accounting for 53.70% of the 
total dental disease events followed by diseases of the pulp with 17.91% of the total dental 
events. Majority of extraction and loss of tooth events had an associated opioid analgesic 
prescription (54.71%) and it represented the dental disease category with the highest rate of 
opioid prescribing following a visit for a dental event. About 42% of dental events involving root 
canal and endodontic treatment procedures were associated with an opioid medication. Summary 
statistics for the opioid prescription rates among the disease categories as well as the mean, 
standard deviation days supply of opioid medication are provided in Table 3. 
Table 3: Opioid prescription rate and mean days supply for different dental event categories 
 
 
 
Dental Events Number of events 
per category 
Proportion 
associated with an 
Opioid medication 
Days supply 
of opioid 
           n       %            n            %     Mean(SD) 
All  16,409 100.00 4,382 26.70 
5.50 (5.57) 
Cleaning, Preventative and Fitting 
procedures 
402 2.44 64 15.92    
15.78(11.12) 
Disorders of Tooth Development 661 4.03 52 7.87 
7.15 (5.99) 
Embedded and Impacted tooth 1,571 9.57 286 18.20 
4.45 (3.52) 
Dental Caries 8,811 53.70 2,055 23.32 
5.61 (6.13) 
Abrasion and Attrition of the teeth 66 0.40 22 33.33 
4.68 (5.85) 
Diseases of the pulp 2,939 17.91 976 33.21 
5.83 (6.86) 
Gum disease, Periodontitis and Gingivitis. 513 12.51 160 31.19 
6.40 (7.07) 
Extraction procedures, Loss of tooth 1,307 7.97 715 54.71 
5.74 (6.53) 
Root Canal and Endodontic Treatment 118 0.72 50  42.37 
10.68 (6.08) 
Developmental Cysts 21     0.13 2 9.52 
5.50 (2.12) 
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Table 4 reports the morphine equivalents doses of opioid prescribed for the ten dental 
event categories by the four categories. MEDD was categorized into four categories: less than 
50, 50 to 89, 90 to 119, greater than 120. Among all dental events, 11.39% of received an opioid 
with a morphine equivalent daily dose (MEDD) greater than 50. About 238 (16.43%) of opioid 
prescriptions for embedded and impacted tooth events were prescribed doses with morphine 
equivalent between 50 and 89. Almost a quarter (13.44%) of opioid prescriptions for abrasions 
and attrition events had an opioid medication with a morphine equivalent greater than 50, while 
approximately 11% of dental caries events had an opioid prescribed with a MEDD greater than 
50. The number and proportion of disease events in each morphine equivalent category are 
reported in Table 4. 
 
Table 4: Morphine equivalent daily dose of opioid prescriptions for different dental events 
Dental events                              Morphine Equivalent Daily Dose 
Less than 50 
    n         % 
50 - 89 
    n        % 
90 - 119 
   n         % 
Greater than 120 
    n              % 
All  3,858 88.04 469 10.70 38 0.70 17 0.39 
Cleaning, Preventative and Fitting 
procedures 53 82.81 7 10.94 1 1.56 3 4.69 
Disorders of Tooth Development 
46 88.46 6 11.54 0 0.00 0 0.00 
Embedded and Impacted tooth 
238 83.22 47 16.43 1 0.35 0 0.00 
Dental Caries 
1,822 88.66 206 10.02 19 0.92 8 0.39 
Abrasion and Attrition of the teeth 19 86.36 3 13.64 0 0.00 0 0.00 
Diseases of the pulp 861 88.22 104 10.66 9 0.82 3 0.31 
Gum disease, Periodontitis and 
Gingivitis. 146 91.25 13 8.13 0 0.00 1 0.63 
Extraction procedures, Loss of tooth 622 86.99 83 11.61 8 1.12 2 0.28 
Root Canal and Endodontic 
Treatment 49 98.00 0 0.00 1 2.00 0 0.00 
Developmental Cysts 
2 100.00 0 0.00 0 0.00 0 0.00 
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iii. Drug level information 
Forty seven percent of all prescriptions were for durations less than 3 days while 83.66% 
of the prescription had durations less than 7 days and over 93% of the prescriptions were for 
durations less than or equal to 15 days. Table 5 shows the days supply categories and 
frequencies for all prescription opioid medications.  
 
Table 5: Days supply of all prescription opioid medications  
Days’ supply n  % 
0-3 days 2,077 47.40 
4-7 days 1,589 36.26 
8-15 days 412 9.40 
16-30 days             290                  6.62 
> 30 days 14 0.32 
 
Table 6 reports the most frequently prescribed opioids for dental related events. 
Hydrocodone, codeine and tramadol collectively accounted for 90.74% of opioid medications 
prescribed for dental related disorders and were the most commonly prescribed medication of 
opioids for dental related events. 
Table 6: Most frequently prescribed opioids for dental related events 
Generic Name n (%) 
Acetaminophen-Hydrocodone 2,536 (57.87) 
Acetaminophen- Codeine  1,048 (23.92) 
Tramadol  392 (8.95) 
Acetaminophen- Oxycodone                              288 (6.57) 
Acetaminophen- Tramadol 35 (0.80) 
Oxycodone  30(0.68) 
Fentanyl  17 (0.39) 
Morphine  15 (0.34) 
Meperidine  9 (0.21) 
Hydromorphone  3 (0.07) 
Hydrocodone- Ibuprofen 4 (0.09) 
Buprenorphine 1 (0.02) 
Oxymorphone  2 (0.05) 
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Morphine- Naltrexone 1 (0.02) 
Butorphanol 1 (0.02) 
OBJECTIVE 2 
Predictors of receiving opioid analgesics following dental related events among 
Mississippi Medicaid beneficiaries  
A logistic regression model using PROC LOGISTIC command in SAS to assess the 
association between the predictor variables (demographic variables, dental visit events and dental 
provider categories) and odds of receiving an opioid medication following a dental visit. 
Race/Ethnicity was not a significant predictor of receiving an opioid following a dental visit. 
Gender was also not a significant predictor of opioid prescriptions. However, age was significant 
with patients 18 years or younger having a lower odds of receiving an opioid in comparison to 
patients ages 19 to 45 years (OR= 0.235, 95% CI: 0.213-0.261, P<0.0001).  
Regarding dental visit events, cleaning, fitting and preventative procedures (the reference 
category), beneficiaries who had a disease of the pulp had a higher odds of receiving an opioid 
analgesic following a dental visit (OR = 2.114, 95% CI: 1.483-3.012, P<0.0001), beneficiaries 
with gum diseases, periodontitis and gingivitis had a higher odd of receiving an opioid analgesic 
(OR = 2.852, 95% CI: 1.564-3.587, p< 0.0001), and  beneficiaries who had had an extraction 
procedure and loss of tooth had a higher odd of receiving an opioid analgesic (OR= 2.852, 95% 
CI: 1.981-4.105, p<0.0001). 
Regarding dental providers, general practice dentists had a higher odd of prescribing 
opioid analgesics following a dental visit in comparison to pediatric dentists (OR=2.336, 95% 
CI: 2.047-2.666, P<0.0001). Table 7 presents the adjusted odds ratio and 95% confidence 
interval for patient variables as well as disease variables associated with an opioid prescription 
after adjusting for differential prescribing patterns by the providers/provider clustering. 
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Table 7: Logistic regression examining predictors of being prescribed an opioid 
Predictors Odds Ratio  95% Confidence 
Interval 
           P-Value 
Race/Ethnicity    
Caucasian  Reference Reference Reference 
Hispanic/Latino 1.402 0.998-1.970 0.0513 
American Indian/Native American 1.522 0.430-5.380 0.5148 
African American 
0.973 0.892-1.063 0.5464 
Other 
0.972 0.768-1.232 0.8169 
Gender 
   
Male 
Reference Reference Reference 
Female 0.953 0.866-1.048 0.3178 
Age    
0-18 0.235 0.213-0.261 <0.0001 
19-45 Reference Reference Reference 
46-59 1.047 0.881-1.245 0.6029 
60+ 0.896 0.576-1.394 0.6273 
Dental events  
   
Cleaning, preventative and fitting 
procedures Reference Reference Reference 
Disorders of tooth development  0.952 0.587-1.542 0.8406 
Embedded and Impacted tooth 0.722 0.498-1.048 0.0863 
Dental Caries 1.267 0.894-1.795 0.1837 
Abrasion and attrition of the teeth 1.778 0.845-3.740 0.1297 
Diseases of the pulp 2.114 1.483-3.012 <0.0001 
Gum diseases, periodontitis and 
gingivitis 2.852 1.564-3.587 <0.0001 
Extraction procedure, Loss of tooth 2.852 1.981-4.105 <0.0001 
Root canal and endodontic treatment  1.675 0.987-2.841 0.0559 
Developmental cysts of the mouth  0.572 0.119-2.751 0.4861 
Dental provider    
General practice dentists 2.336 2.047-2.666 <0.0001 
Pediatric dentists Reference Reference Reference 
Oral and Maxillofacial surgeons 1.084 0.956-1.228 0.2084 
Other dental providers 1.080 0.921-1.265 0.3442 
*P <0.05; ** P <0.0001 
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Table 8 shows results of a logistic regression model using PROC LOGISTIC to show the 
association between the predictor variables (demographic variables, dental visit events and dental 
provider categories) with the outcome of the odds of receiving an opioid medication with a 
morphine equivalent greater than 25 MEDD (median value) following a dental related visit. 
African Americans had a slightly lower odd of receiving an opioid medication with a 
morphine equivalent greater than 25 compared to Caucasians (OR= 0.867, 95% CI: 0.784-0.970, 
P= 0.0115) while Hispanics/Latinos have a lower odd of receiving an opioid medication with a 
morphine equivalent greater than 25 compared to Caucasians (OR= 0.360, 95% CI: 0.164-0.790, 
P= 0.0109). Patients aged 18 years or below had a much lower odd (OR=0.097, 95% CI: 0.083-
0.112, P<0.0001) of receiving opioid with a morphine equivalent greater than 25. 
  Regarding dental events and the odd of receiving an opioid with a morphine equivalent 
higher than 25, compared to the reference category (cleaning, fitting and preventative 
procedures), patients with abrasion and attrition of the teeth had a higher odd (OR= 2.585, 95% 
CI: 1.155-5.787, P=0.0209), patients with diseases of the pulp had a higher odd (OR= 1.877, 
95% CI: 1.211-2.908, P=0.0049), gum diseases periodontitis and gingivitis (OR =2.764, 95% CI: 
1.672-4.568, P<0.0001), extraction and loss of tooth procedure (OR= 2.100 95% CI: 1.346-
3.278, P=0.0011), root canal and extraction procedures (OR=2.757, 95% CI: 1.524-4.987, 
P=0.0008) have a higher odd of receiving an opioid medication with a morphine equivalent 
greater than 25.  
Regarding dental providers, compared to the reference category of pediatric dentists, general 
practice dentists had a higher odd of prescribing an opioid with a morphine equivalent greater 
than 25 (OR=3.734, 95% CI: 3.181-4.382, p<0.0001), oral and maxillofacial surgeons had a 
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higher odd of prescribing opioids with a morphine equivalent greater than 25 (OR=1.734, 95% 
CI: 1.486-2.023, P<0.0001).  
Table 8: Logistic regression examining association between predictor variables and the odds of 
being prescribed an opioid with morphine equivalent dose greater than 25 
Predictors Odds Ratio  95% Confidence 
Interval   
           P-Value 
Race/Ethnicity    
Caucasian  Reference Reference Reference 
Hispanic/Latino            0.360 0.164-0.790 0.0109* 
American Indian/Native American 0.403 0.048-3.409 0.4042 
African American 
0.872 0.784-0.970 0.0115* 
Other 
0.845 0.637-1.121 0.2426 
Gender 
   
Male 
Reference Reference Reference 
Female 0.989 0.873-1.119 0.8557 
Age    
0-18 0.097 0.083-0.112 <0.0001** 
19-45 Reference Reference Reference 
46-59 0.870 0.717-1.056 0.1601 
60+ 1.098 0.680-1.771 0.7021 
Dental events  
   
Cleaning, preventative and fitting 
procedures Reference Reference Reference 
Disorders of tooth development  1.011 0.548-1.866 0.9713 
Embedded and Impacted tooth 1.241 0.784-1.963 0.3565 
Dental Caries 1.219 0.791-1.880 0.3698 
Abrasion and attrition of the teeth 2.585 1.155-5.787 0.0209* 
Diseases of the pulp 1.877 1.211-2.908 0.0049* 
Gum diseases, periodontitis and 
gingivitis 2.764 1.672-4.568 <0.0001** 
Extraction procedure, Loss of tooth 2.100 1.346-3.278 0.0011* 
Root canal and endodontic treatment  2.757 1.524-4.987 0.0008* 
Developmental cysts of the mouth  1.515 0.289-7.930 0.6229 
Dental provider    
General practice dentists 3.734 3.181-4.382 <0.0001** 
Pediatric dentists Reference Reference Reference 
Oral and maxillofacial surgeons 1.734 1.486-2.023 <0.0001** 
Other dental providers 1.298 1.071-1.573 0.0079* 
*P <0.05; ** P <0.0001 
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OBJECTIVE 3 
Prevalence of opioid analgesics prescribing for dental related emergency departments (ED) 
related visits in the Mississippi Medicaid population  
Study sample 
In the 2015 and 2016 Mississippi division of Medicaid data, a total of 2,574 beneficiaries 
had a dental related ED visit, and among these, 1,176 had an opioid prescription claim within 24 
hours. Figure 2 shows the sample selection chart for patient level information. 
 
 
 
 
 
  
 
 
 
 
 
                                                   
 
 
                  
                      Figure 2: Sample selection chart (Patient level information) for ED related visits 
 
 
 
 
1. Demographic/Patient level information dental related ED visits 
African Americans accounted for a little over 60% of the population using the emergency 
department for dental visits, while Caucasians made up 35.04% of the population. Females 
accounted for 77.74% of beneficiaries using the ED for dental related events. Only 14.41% 
of the sample population was 18 years or younger, while 75.87% of the population is 
between the ages of 19 to 44 years. Table 9 reports descriptive statistics of the total 
population using the ED for dental events. 
Beneficiaries identified 
with an ED visit related to 
a dental event in the study 
period 
 
2,574 
 
 
 
12,388 
 
 
Beneficiaries with a 
claim for an opioid 
analgesic medication 
within 24 hours   
 
1,176 
 
 
 
12,388 
 
 
Beneficiaries without a 
claim for an opioid 
analgesic medication 
within 24 hours   
 
1,398 
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Table 9: Sample characteristics of patients using ED for dental related events. 
Demographic Characteristics 
n=2,574 
 
                 n                                      % 
Age (Mean= 29.71, SD=11.15)   
 0-18 years 371 14.41 
19-44 years 1,953 75.87 
45-59 years 224 8.70 
60+ years 26 1.01 
Race/Ethnicity   
Caucasian 902 35.04 
African American 1,571 61.03 
Hispanic 13 0.51 
American Indian 5 0.19 
Other 83 3.22 
Gender   
Female  2,001 77.74 
Male 573 22.26 
 
Approximately 45% of African Americans who used the ED for dental related events 
were prescribed an opioid analgesic medication within 24 hours, while the rate of prescription 
among Caucasians was 46.78%. Among patients 18 or younger who used the ED for dental 
related events, more than half (51.2%) received an opioid analgesic medication while 
approximately 45% of patients aged 19-44 years who used the ED for a dental related event 
received an opioid medication. About 48% of males using the ED for dental related events 
received an opioid analgesic medication while 45% of females received an opioid. Table 10 
provides the proportion of patients receiving an opioid within 24 hours following at least one 
dental ED visit. 
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Table 10: Proportion of patients receiving an opioid within 24 hours following a dental ED visit 
Demographic Characteristics 
n=2,574 
   Total Population  
                         n 
    Proportion receiving an opioid 
                     n                        % 
All                      2,574                   1,176                 45.70 
Age (Mean= 29.71, SD=11.15)    
 0-18 years 371 190 51.21 
19-44 years 1,953 883 45.21 
45-59 years 224 95 42.41 
60+ years 26 8 30.77 
Race/Ethnicity    
Caucasian 902 422 46.78 
African American 1,571 708 45.07 
Hispanic 13 7 53.85 
American Indian 5 2 40.00 
Other 83 37 44.58 
Gender    
Female  2001 902 45.08 
Male 573 274 47.82 
 
2. Event level information for ED related dental visits  
A total of 3,417 dental events related to ED visits were identified. Dental events were 
categorized into ten distinct categories. Summary statistics for the opioid prescription rates 
among the disease categories encountered in the ED as well as the mean and standard 
deviation of days supply of opioid medication were calculated. 
Overall, 41.59% of all dental related visits to the emergency room had an associated 
opioid medication prescription. Approximately 42% of ED dental events related to dental 
caries had an associated opioid prescription, while 48% of ED visits related to gum disease 
and gingivitis received an opioid medication. Dental caries was the most common event 
category encountered with 39.04% of the total dental disease events in the ED followed by 
diseases of the pulp with 33.60% of dental ED visits. Table 11 reports opioid prescription 
rate and mean days supply for dental related ED visits. 
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Table 11: Opioid prescription rate and mean days supply for dental related ED visits 
 
 
 
Table 12 reports the morphine equivalents(MEDD) of opioid prescribed for ED visits 
related to dental event categories subdivided into four morphine equivalents: less than 50, 50 to 
89, 90 to119, greater than 120. The number and proportion of events in each morphine 
equivalent category is also shown below in Table 12. 
 
 
 
 
 
Dental event category Number of events per 
category 
Proportion     
associated with 
an Opioid 
medication 
Days 
supply of 
opioid 
      n  %  n    % Mean(SD) 
All 
3,417 
100.0
0 1,421 41.59 
5.50 
(5.57) 
Cleaning, Preventative and Fitting 
procedures 2 0.06 1 50.00 
             
15.00 (-) 
Disorders of Tooth Development 
7 0.20 4 57.14 
3.75 
(2.87) 
Embedded and Impacted tooth 
47 1.38 20 42.55 
3.40 
(2.13) 
Dental Caries 
1,334 39.04 563 42.20 
4.98 
(5.45) 
Abrasion and Attrition of the teeth 
24  0.70 5 20.83 
3.40 
(1.67) 
Diseases of the pulp 
1,148 33.60 469 40.85 
4.83 
(5.23) 
Gum disease, Periodontitis and 
Gingivitis. 100 2.93 48 48.00 
6.48 
(7.42) 
Extraction procedures, Loss of 
tooth 743 21.74 307 41.32 
5.06 
(5.36) 
Root Canal and Endodontic 
Treatment 11 0.32 4  36.36 
4.50 
(2.08) 
Developmental Cysts 
1 0.03 0 0.00 
- (-) 
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Table 12: Morphine equivalent daily dose (MEDD) of opioid prescriptions for ED related dental 
diseases 
 
3. Drug level information on dental related ED visits 
Regarding opioid medication variables, approximately 53% of all prescriptions in the ED 
were for durations less than 3 days while 87.40% of the prescriptions following an ED visit had 
durations less than 7 days. Table 13 reports the days’ supply of prescribed opioid medications  
following a dental related E.D visit. 
 
Table 13: Days’ supply of prescribed opioid medications for  
dental related ED visits 
Days’ supply n  (%) 
0-3 days 754 53.06 
4-7 days 488 34.34 
8-15 days 119 8.37 
Dental Disease Category                                Morphine Equivalent Daily Dose 
Less than 50 
    n         % 
50 - 89 
    n        % 
90 - 119 
   n         % 
Greater than 120 
     n          % 
All procedures 1,264 88.95 145 10.20 11 0.77 1 0.07 
Cleaning, Preventative and Fitting 
procedures 
1 100.00 0 0.00 0 0.00 0 0.00 
Disorders of Tooth Development 4 100.00 0 0.00 0 0.00 0 0.00 
Embedded and Impacted tooth 15   75.00      5 25.00 0 0.00 0 0.00 
Dental Caries 498 88.45 63 11.19 2 0.36 0 0.00 
Abrasion and Attrition of the teeth 3 60.00 2 40.00 0  0.00 0 0.00 
Diseases of the pulp 419 89.34 47 10.02 3 0.64 0 0.00 
Gum disease, Periodontitis and 
Gingivitis. 
45 93.75 3 6.25 0 0.00 0 0.00 
Extraction procedures, Loss of tooth 275 89.58 25 8.14 6 1.95 1 0.33 
Root Canal and Endodontic Treatment 4 100.00 0 0.00 0 0.00 0 0.00 
Developmental Cysts 0 0.00 0 0.00 0 0.00 0 0.00 
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16-30 days             57                4.01 
> 30 days 3 0.21 
Hydrocodone accounted for about 62% of opioid prescription in the ED, while codeine 
was prescribed for about 17% of opioid prescriptions following a dental related ED visit. 
Hydrocodone, Codeine and Tramadol collectively accounted for 92.58% of opioid medications 
prescribed for dental related disorders following an ED visit. Table 14 reports the most 
frequently prescribed opioids following dental related ED visits. 
 
Table 14: Most frequently prescribed opioids following dental related ED visits 
Generic Name n (%) 
Acetaminophen-Hydrocodone 886 (62.35) 
Acetaminophen- Codeine  
238 (16.75) 
Tramadol  
192(13.51) 
Acetaminophen- Oxycodone 
75(5.28) 
Acetaminophen- Tramadol 17 (1.20) 
Hydrocodone- Ibuprofen  5 (0.35) 
Oxycodone  3 (0.21) 
Morphine  
2 (0.14) 
Meperidine  1 (0.07) 
Fentanyl 
1 (0.03) 
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CHAPTER V 
DISCUSSION 
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OBJECTIVE 1 
Prevalence of opioid analgesics prescribing for non-ED dental related visits in the Mississippi 
Medicaid population 
In this study, we sought to assess various trends in opioid analgesic prescribing for dental 
related visits using the Mississippi Medicaid database. The results of the study indicate that 
dental related problems are a prominent source of opioid prescribing. Based on previous research 
by Levy et al, a study using IMS national prescription audit data on opioid prescription volume 
by specialty, showed that dentists prescribed 6.4% of all opioids; and this translates to millions 
of prescriptions (Levy, Paulozzi, Mack, & Jones, 2015).  
In our study, we found that dental caries was the most frequently encountered dental 
disease category. The following dental event categories: (1) tooth extraction procedures and 
other conditions involving loss of tooth, (2) root canal treatment and endodontic therapies, (3) 
embedded and impacted tooth, (4) diseases of the pulp and (5) dental caries had a higher odd of 
receiving an opioid analgesic prescription following a visit, compared to cleaning and 
preventative procedures. These observations are consistent with other research showing that root 
canal procedures, periodontics’ treatment had a high odd of receiving an opioid prescription per 
visit to the dentist (Steinmetz et al 2017). 
Our study also suggests a lower rate of opioid prescribing among children 18 years and 
younger. In this study, the rate of opioid prescriptions ages 18 years and younger was about 
10.59%. This finding is in line with another study conducted using the National Medicaid 
analytic extract files to assess the proportion of Medicaid patients dispensed opioids following 
surgical extraction of teeth. In the 2000-2010 data, they found that 14% of children under 13 and 
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61% of children under 18 years of age received of opioid prescription for dental extraction 
procedures. (Baker, J. A., Avorn, J., Levin, R., & Bateman, B. T., 2016). Another study 
conducted in Canada reported that 50% of children in their study received codeine for less than 3 
days (Etminan, M., Nouri, M. R., Sodhi, M., & Carleton, B. C., 2017). The rate of opioid 
prescribing among children in our study is lower (11%) than other studies showing similar rates 
of opioid prescriptions among children.  However, this could be due to the increased awareness 
regarding the danger of opioid prescription in the United States.  
In our study, morphine equivalent dose of opioids prescribed to patients following dental 
procedures indicates that the majority of patients in most disease categories received an opioid 
with a morphine equivalent dose less than 50. However, a small proportion of patients received 
opioids with morphine equivalent doses greater than 50 for dental events. The Centers for 
Disease Control and Prevention (CDC) has issued guidelines which encourage clinicians to use 
caution when prescribing opioids at any dosage. Additionally, they should carefully reassess 
evidence of individual benefits and risks when considering increasing dosage to 50 morphine 
milligram equivalents or higher (Dowell, D., Haegerich, T. M., & Chou, R., 2016).  
In our study, drug level information indicated that hydrocodone, codeine and tramadol 
were the most frequently prescribed opioids following a dental related condition. This finding is 
consistent with previous studies on the most frequently prescribed opioids following dental 
extraction which showed that hydrocodone, oxycodone, propoxyphene and codeine as the most 
commonly prescribed opioids following tooth extraction (Baker, J. A., Avorn, J., Levin, R., & 
Bateman, B. T., 2016). These results indicate the need to provide adequate information to 
dentists to prevent inappropriate prescribing of opioids to patients who may otherwise be 
adequately treated for pain with other classes of analgesics. 
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OBJECTIVE 2 
Predictors of receiving opioid analgesics following dental related events among Mississippi 
Medicaid beneficiaries 
A logistic regression model predicting the odds of receiving an opioid medication for 
dental visits was developed. Our findings indicate that the prescribing of opioid analgesic 
medication for dental related pain and the odds of receiving an opioid medication is higher 
among Hispanics, patients with diseases of the pulp, patients that have undergone a tooth 
extraction procedure or a root canal treatment and patients with gum disease or periodontitis. 
This observation is in line with previous literature on opioid analgesic prescribing for dental 
diseases and socioeconomic status showing that minorities had a higher odd of opioid 
prescriptions for dental diseases (Steinmetz et al, 2017). Our study indicates that regarding 
providers, compared to the reference category of pediatric dentists, general practice dentists, oral 
and maxillofacial surgeons had a higher odd of prescribing opioids. 
A logistic regression analysis was modeled to predict the odds of receiving an opioid 
medication with a morphine equivalent dose greater than 25 morphine equivalent daily dose 
which was the median morphine equivalent in the study population. Our findings indicated that 
beneficiaries 18 years or younger, had a lower odd of receiving an opioid with a MEDD of 25 or 
more, while patients with diseases of the pulp, gum diseases or had undergone an extraction 
procedure have a higher odd of receiving an opioid medication with a dose greater than 25 
morphine equivalents. Furthermore, opioid prescribing dosage is important due to CDC 
guidelines on clinicians being encouraged to understand the benefits and risks when considering 
increasing opioid dosage to 50 morphine milligram equivalents (MME)/day or greater (Dowell, 
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D., Haegerich, T. M., & Chou, R., 2016). Our study indicates that regarding providers, compared 
to the reference category of pediatric dentists, general practice dentists, oral and maxillofacial 
surgeons had a higher odd of prescribing opioids. 
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OBJECTIVE 3 
Prevalence of opioid analgesics prescribing for emergency departments (ED) related visits in 
the Mississippi Medicaid population 
In this study, we used data from Mississippi Medicaid to assess various trends in opioid 
use following emergency department (ED) visits for dental conditions. In our study, dental caries 
accounted for the most frequent dental disease category encountered in ED visits. Gum diseases, 
loss of tooth and extraction procedures, dental caries, diseases of the pulp all accounted for high 
proportion of opioid prescriptions following an ED visit. An observational multicenter study on 
general ED visits showed that among patients whose chief complaint and primary discharge 
diagnosis was associated with an opioid medication after an ED visit, 5.9% were related to dental 
pain and 6.2% was related to a dental or oral issue representing 12.1% of total emergency visits 
due to pain (Hoppe, J. A., Nelson, L. S., Perrone, J., Weiner, S. G., 2015). This indicates a 
potential reliance on emergency departments for treatment by some patients with dental 
problems. 
Our study also suggests a low rate of opioid prescription following ED use for dental pain 
among children ages 18 years or younger (14.41%). Approximately 76% of patients receiving 
opioids following emergency department visit for dental related diseases were between the ages 
of 19 and 44 years. This trend observed in this study is supported by prior research studies which 
reported that most patients using ED services associated with dental pain were young adults 
between the ages of 19 and 33 years (Okunseri, C., Okunseri, E., Xiang, Q., Thorpe, J. M., & 
Szabo, A., 2014).   
Morphine equivalent dose of opioids prescribed to patients following ED dental 
procedures also shows that a clear majority of patients in most disease categories received an 
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opioid with a morphine equivalent dose less than 50. However, a small proportion of patients 
received opioids with morphine equivalent doses greater than 50 after an ED visit. Our study 
found that hydrocodone was the most commonly prescribed opioid analgesic for ED visits was 
hydrocodone (62.35%) followed by codeine (16.75%) and finally tramadol (13.51%). A previous 
study on types of opioid analgesics prescribed in the ED revealed that the most frequently 
prescribed opioid medications in the ER are oxycodone (52.3%), hydrocodone (40.9%), and 
codeine (4.8%) and that 90% of prescribed opioids were combination products with analgesics 
like ibuprofen and acetaminophen (Hoppe, J. A., Nelson, L. S., Perrone, J., Weiner, S. G. 2015).  
 
Limitations 
There are several limitations to the study. First, the study was conducted using Medicaid 
administrative claims data and therefore there is a possibility of misclassification of dental 
diseases due to coding errors during claims processing. Also, it is possible to have some opioid 
analgesic prescription claims not related to dental visits included in the study, possibly due to 
multiple visits in the same time frame by beneficiaries to multiple providers in the same hospital 
including dentists. Days’ supply of opioid used in the calculation could be altered by the 
pharmacy processing claim to ease payment by insurance thereby potentially confounding the 
morphine equivalent dosage calculations. Classification of race/ethnicity was determined by 
hospital staff based on perception of the hospital staff. Additionally, our findings might not be 
generalizable to the general population or representative of opioid utilization in the general 
population due to the data being state specific with a population that is generally below the 
poverty line.  
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Conclusions 
This study is significant because it identifies and characterizes opioid prescription use in 
dental conditions and gives us an understanding of how specific dental events and demographic 
factors that contribute to receiving opioid prescriptions following a dental visit in the ED and 
non-ED setting.  
Due to the current CDC warning of provider caution in prescribing opioids with dosage 
greater than 50 morphine equivalents, this study identifies predictors of high opioid dosage in 
dental patients and utilizes statistical techniques to assess the relationship between 
sociodemographic and dental disease variables and high opioid doses for dental related events.  
In conclusion, this study has a broader policy implication for the state of Mississippi 
regarding opioid abuse and misuse, drug utilization trend monitoring and curtailing opioid abuse 
by broadening the lens to the field of dentistry. 
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Appendix A: FDA approved opioid analgesic medications 
 Generic Name Brand Names (examples) 
1.  Alfentanil Alfenta 
2.  Buprenorphine Belbuca, Buprenex, Butrans 
3.  Butorphanol No brand name currently marketed 
4.  Codeine Fioricet w/ codeine, Fiorinal w/ codeine, Soma Compound 
w/ codeine, Tylenol w/ codeine 
5.  Dihydrocodeine Synalgos-DC 
6.  Fentanyl Abstral, Actiq, Duragesic, Fentora,  
7.  Hydrocodone Anexsia, Hysingla ER, Lortab, Norco, Reprexain, Vicodin 
8.  Hydromorphone Dilaudid, Dilaudid-HP, Exalgo 
9.  Meperidine Demerol 
10.  Methadone Dolophine 
11.  Morphine Astramorph PF, Duramorph PF, Embeda, Infumorph, 
Kadian 
12.  Nalbuphine Nubain 
13.  Oxycodone Oxaydo, Oxycet, Oxycontin, Percocet, Percodan, Roxicet 
14.  Oxymorphone Opana, Opana ER 
15.  Pentazocine Talwin 
16.  Remifentanil Ultiva 
17.  Sufentanil Sufenta 
18.  Tapentadol Nucynta, Nucynta ER 
19.  Tramadol Conzip, Ultracet, Ultram, Ultram ER 
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Appendix B: Dental Disease Categories, Dental Related ICD-9 and ICD-10 Diagnosis Codes 
Dental 
Disease 
Category 
Diagnosis ICD-9 Code ICD-10 Code 
1 Cleaning, preventative and fitting procedures    
 Encounter for dental examination and cleaning without 
abnormal findings  
 
V722 Z01.20 
 Encounter for dental examination and cleaning with 
abnormal findings 
V722 Z01.21 
 Encounter for fitting and adjustment of orthodontic 
device 
V53.40,V58.50 Z46.4 
    
2 Disorders of tooth development   
 Supernumerary teeth 520.1 K00.1 
 Abnormalities of size and form of teeth 520.2 K00.2 
 Mottled teeth 520.3 K00.3 
 Disturbances in tooth formation 520.4 K00.4 
 Hereditary disturbances in tooth structure 520.5 K00.5 
 Disturbances in tooth eruption 520.6 K00.6 
 Teething syndrome 520.7 K00.7 
 Other disorders of tooth development 520.8 K00.8 
 Disorder of tooth development, unspecified 520.9 K00.9 
3 Embedded and Impacted tooth   
 Embedded teeth 520.6 K01.0 
 Embedded teeth 520.6 K01.1 
4 Dental Caries   
 Dental caries on smooth surface limited to enamel 521.01, 521.02 K02.61 
 Dental caries on smooth surface penetrating into 
dentin 
521.02, 521.07 K02.62 
 Dental caries on the smooth surface penetrating into 
the pulp 
521.03, 521.07 K02.63 
 72 
5 Abrasion and attrition of the teeth   
 Excessive attrition of teeth 521.10, 521.11, 
521.12, 521.13, 
521.14, 521.15 
K03.0 
 Abrasion of teeth 521.20, 521.21, 
521.22, 521.23, 
521.24, 521.25 
K03.1 
 Erosion of the teeth 521.30, 521.31, 
521.32, 521.33, 
521.34, 521.35 
K03.2 
 Pathological resorption of teeth 521.40, 521.41, 
521.42, 521.49 
K03.3 
 Deposits [accretions] on teeth 523.60 K03.6 
6 Disease of the pulp   
 Necrosis of the pulp 522.10 K04.1 
 Pulp degeneration 522.20 K04.2 
 Abnormal hard tissue formation in pulp 522.30 K04.3 
 Acute apical periodontitis of pulpal origin 522.40 K04.4 
 Periapical abscess without sinus 522.50 K04.7 
7 Gum, periodontal and gingival diseases   
 Periodontosis 523.50 K05.4 
 Other periodontal diseases 523.80 K05.5 
 Gingival enlargement 523.80 K06.1 
 Gingival and edentulous alveolar ridge lesions 
associated with trauma 
523.80 K06.2 
8 Extraction and loss of tooth   
 Partial loss of teeth due to trauma, unspecified class 525.11 K08.419 
 Partial loss of teeth due to periodontal diseases, 
unspecified class 
525.12 K08.429 
 Partial loss of teeth due to caries, unspecified class 525.13 K08.439 
 Loss of tooth due to fracture 873.63, 873.73 S02.5 
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9 Developmental cysts of the oral region   
 Developmental (nonodontogenic) cysts of oral region 526.10 K09.1 
10 Root canal and endodontic treatment   
 Perforation of root canal space due to endodontic 
treatment 
526.61 M27.51 
 Endodontic overfill 526.62 M27.52 
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